TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›IMCR›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

Immunocore Holdings plc (IMCR) financials

Income statement

Immunocore Holdings plc (IMCR) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$4.08M$174M$249M$310M$400M
Revenue growth—4175.6%43.1%24.4%29.0%
Operating income-$175M-$51.7M-$59.6M-$70.5M-$45.4M
Operating margin-4281.2%-29.7%-23.9%-22.7%-11.3%
Net income-$180M-$52.5M-$55.3M-$51.1M-$35.5M
Net margin-4414.6%-30.1%-22.2%-16.5%-8.9%
EPS (diluted)-$4.24-$1.15-$1.13-$1.02-$0.71

Cash flow

Immunocore Holdings plc (IMCR) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow-$143M-$49.2M$2.94M$26.1M-$10.7M
Capital expenditures$1.39M$2.20M$5.42M$5.17M$4.34M
Free cash flow-$144M-$51.4M-$2.48M$20.9M-$15.1M

Balance sheet

Immunocore Holdings plc (IMCR) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents$321M$402M$443M$456M$468M
Total assets—$527M$597M$1.01B$1.07B
Total liabilities—$188M$228M$649M$686M
Shareholders' equity$234M$339M$369M$361M$381M
Retained earnings—-$689M-$745M-$796M-$831M
Shares (wtd avg diluted)42.5M45.7M48.9M50.0M50.3M

Every figure is extracted from Immunocore Holdings plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Immunocore Holdings plc's annual revenue?
Immunocore Holdings plc (IMCR) reported $400M of revenue for fiscal year 2025 — up 29.0% from $310M in FY2024, per its annual report filed with the SEC.
Is Immunocore Holdings plc profitable?
Not in FY2025 — IMCR reported a net loss of $35.5M, per SEC filings.
What is Immunocore Holdings plc's free cash flow?
-$15.1M in FY2025 (operating cash flow -$10.7M minus $4.34M of capital expenditures), from the SEC cash-flow statement.
Does IMCR pay a dividend?
Immunocore Holdings plc reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full IMCR analysis — verdict, score & filings →Is IMCR a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.